LEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab
In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.
Skin Cancer News
SKIN CANCER ADVISOR
Skin Cancer News
Neoadjuvant Nivolumab Plus Relatlimab Produced a High pCR Rate in Stage III-IV Melanoma
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Greater Benefit With Pembrolizumab in Crossover vs Rechallenged Patients With Cutaneous Melanoma
Patients were more likely to benefit from pembrolizumab if they had not previously received the drug.
Adjuvant Pembrolizumab Improves RFS, Not OS, in Resected High-Risk Melanoma
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Lifileucel Could Be a New Standard of Care for Patients With Heavily Pretreated Metastatic Melanoma
Lifileucel has produced responses lasting more than 2 years in patients with limited treatment options.
New Checkpoint Inhibitor Relatlimab Works With Nivolumab to Improve PFS in Melanoma
This is the first phase 3 study to validate LAG-3 inhibition as a therapeutic strategy in cancer, according to an investigator.
Systemic and Local Therapeutic Approaches Aim to Improve Overall Response in Cutaneous Melanoma
Therapeutic combinations of immune checkpoint blockade with targeted, oncolytic, or antiangiogenic approaches are promising for patients with cutaneous melanoma.
Adjuvant Pembrolizumab Is Not Associated With Reduced Quality of Life in Resected Stage III Melanoma
Researchers findings support the use of pembrolizumab in patients with resected stage III melanoma.
Early TMTV Changes on FDG-PET/CT Predict Long-Term Outcomes in Patients Treated With Pembrolizumab for Advanced Melanoma
Changes 2 to 4 months after the start of therapy with pembrolizumab may predict long-term response and survival.
Emerging Biomarkers in Stage III Melanoma May Improve Patient Management
Gene expression analysis and the identification of a single gene or a signature correlated with patients’ outcomes could lead to improved patient stratification.
Low Risk of Lymphoma, But Not Other Cancers, With Topical Calcineurin Inhibitors
TCI use also resulted in an increased risk of lymphoma in the 3 studies with topical corticosteroid comparators.
Anti-PD-1 Therapy Is Associated With Chronic Immune-Related Adverse Events in Patients With Melanoma
Researchers found that low grade irAEs after anti-PD-1 therapy were more common than previously reported and frequently persist after prolonged follow-up.
MMS Performed at Academic Facilities Improves Melanoma Survival
Melanoma excised with Mohs micrographic surgery, those treated at academic and higher-volume facilities had improved long-term survival.
Low Incidence of Skin Cancer After Liver Transplant in Non-White Patients
Because of immunosuppressive therapy following liver transplantation, de novo malignancies can occur, and the most common are skin cancers.
Risk for Cutaneous Squamous Cell Carcinoma Increases With Age
Among patients younger than 49 years, those with actinic keratosis had a nearly 7-times greater likelihood of developing cutaneous squamous cell carcinoma than patients without actinic keratosis.
Past Decade Has Seen Improved Outcomes in Melanoma Brain Metastasis
A team of investigators sought to assess the impact of multimodality, CNS-directed treatments on survival rates in patients with melanoma brain metastasis.
COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Blood Cell Score for Identifying Aggressive Melanoma
A team of investigators created the myeloid index score, which captures the prognostic value of blood myeloid cells and may be used in the management of patients with melanoma.
Patterns in the Development of Melanoma Across Body Sites
A team of international researchers sought to confirm a “dual pathway hypothesis” for the development of melanoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Skin Cancer
Loading... 
Loading...